Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) in breast cancer. Is it cost-effective?

被引：0
|
作者：
Norum, J [1 ]
机构：
[1] Univ Tromso Hosp, Dept Oncol, N-9012 Tromso, Norway
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81319-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
899
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [11] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    KJ O'Byrne
    MI Koukourakis
    MP Saunders
    AJ Salisbury
    R Isaacs
    S Varcoe
    M Taylor
    TS Ganesan
    AL Harris
    DC Talbot
    British Journal of Cancer, 1998, 77 : 1950 - 1956
  • [12] Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
    Poole, Christopher J.
    Earl, Helena M.
    Hiller, Louise
    Dunn, Janet A.
    Bathers, Sarah
    Grieve, Robert J.
    Spooner, David A.
    Agrawal, Rajiv K.
    Fernando, Indrajit N.
    Brunt, A. Murray
    O'Reilly, Susan M.
    Crawford, S. Michael
    Rea, Daniel W.
    Simmonds, Peter
    Mansi, Janine L.
    Stanley, Andrew
    Harvey, Peter
    McAdam, Karen
    Foster, Liz
    Leonard, Robert C. F.
    Twelves, Christopher J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (18): : 1851 - 1862
  • [13] Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer
    Colleoni, M
    Price, K
    Castiglione-Gertsch, M
    Goldhirsch, A
    Coates, A
    Lindtner, J
    Collins, J
    Gelber, RD
    Thürlimann, B
    Rudenstam, CM
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) : 1693 - 1700
  • [14] CLINICAL CONTROLLED TRIAL IN ADVANCED BREAST-CANCER - CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CMF+T (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, TAMOXIFEN)
    HINDY, I
    NEOPLASMA, 1985, 32 (03) : 381 - 387
  • [15] Zoledronic acid - a cost-effective Therapy in the adjuvant Situtation of Women with a Breast cancer.
    Lux, M. P.
    Reichelt, C.
    Wallwiener, D.
    Kreienberg, R.
    Jonat, W.
    Gnant, M.
    Beckmann, M. W.
    ONKOLOGIE, 2010, 33 : 39 - 39
  • [16] 5FU (5 fluorouracil) infusion duration and toxicity during CMF (cyclophosphamide, methotrexate, 5 fluorouracil) administration in adjuvant setting of breast cancer
    Capobianco, Alba M.
    Tartarone, Alfredo
    Coccaro, Mariarosa
    Di Leo, Pasquale
    Bochicchio, Annamaria
    Ardito, Raffaele
    Rionero, Crob
    ANNALS OF ONCOLOGY, 2006, 17 : 109 - 109
  • [17] CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL FOR BREAST-CANCER
    HOWELL, A
    GEORGE, WD
    CROWTHER, D
    RUBENS, RD
    BULBROOK, RD
    BUSH, H
    HOWAT, JMT
    SELLWOOD, RA
    HAYWARD, JL
    FENTIMAN, IS
    CHAUDARY, M
    LANCET, 1984, 2 (8398): : 307 - 311
  • [18] Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
    Colleoni, M
    Price, KN
    Castiglione-Gertsch, M
    Gelber, RD
    Coates, AS
    Goldhirsch, A
    LANCET, 1999, 354 (9173): : 130 - 131
  • [19] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [20] Cost effectiveness of adjuvant chemotherapy with cyclophosphamide plus methotrexate plus fluorouracil in patients with node positive breast cancer
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (02) : 111 - 116
12345